To learn more about the International OCD Foundation’s 23rd Annual OCD Conference, please visit http://ocd2016.org.
Back To Schedule
Friday, July 29 • 8:00am - 9:00am
Novel Treatments for OCD: Recent Studies of Glutamate Modulators

Sign up or log in to save this to your schedule, view media, leave feedback and see who's attending!

Standard first-line treatments for OCD include cognitive behavioral therapy (CBT), pharmacotherapy with serotonin reuptake inhibitors (SRIs), and their combination. Unfortunately, these are ineffective in up to 1/3 of patients; there is thus an urgent need for alternative treatments. Much interest has focused on modulators of the brain's glutamate system. This symposium will summarize recent work on glutamate modulators in the treatment of refractory OCD. Current data implicating glutamate as a possible contributor to the pathophysiology of OCD will be summarized, as will specific studies on the glutamatergic drugs ketamine and riluzole. Early data on the combination of glutamate modulators with psychotherapy will be presented, along with prospects for and obstacles to progress in this area in the near term.


Christopher Pittenger, MD, PhD

Christopher Pittenger is Associate Professor of Psychiatry at Yale and Director of the Yale OCD Research Clinic. He received his MD-Ph.D. from Columbia University, where his Ph.D. studies, performed with Nobel Prize winner Eric Kandel, focused on elucidating the mechanisms... Read More →

Carolyn Rodriguez, MD, PhD

Dr. Carolyn Rodriguez is an Assistant Professor of Psychiatry at Stanford and Director of the Stanford Translational OCD Research Program. After graduating from Harvard University, she completed the M.D.-Ph.D. program at Harvard Medical School and M.I.T. Her lab utilizes an... Read More →

Friday July 29, 2016 8:00am - 9:00am CDT
Avenue Ballroom, 4th Floor